Pharma Company's Rs. 47.7L Marketing Expenses Ruled Fully Deductible; Tribunal Dismisses Revenue's Appeal.

The Tribunal upheld the CIT(A)'s decision, ruling that the expenditure of Rs. 47,71,110 incurred by the pharmaceutical company for marketing purposes was of a revenue nature and fully deductible. The Tribunal dismissed the Revenue's appeal, emphasizing that the classification of the expenditure as 'deferred revenue expenditure' in the books did not affect its deductibility and that the enduring benefit test was not conclusive. The Tribunal aligned with the CIT(A) in determining that the expenses facilitated trading operations without impacting fixed capital, thus confirming the assessee's claim for full deduction.

---

---

Issues Involved:
1. Whether the expenditure of Rs. 47,71,110 should be treated as revenue or capital expenditure.
2. Whether the treatment of the expenditure as 'deferred revenue expenditure' in the books of account affects its deductibility.

Issue 1: Treatment of Expenditure as Revenue or Capital
The Revenue appealed against the CIT(A)'s order treating the expenditure of Rs. 47,71,110 as revenue in nature and deleting the disallowance made by the AO, who treated it as capital expenditure. The assessee, a pharmaceutical company, incurred this expenditure on marketing its products and treated it as deferred revenue expenditure in its books, claiming only 1/10th of the expenses as a deduction in the P&L account. However, in the computation of income, the assessee claimed the entire amount as deductible. The AO argued that the expenditure provided benefits over several years and should be capitalized. The CIT(A) disagreed, stating that the nature of the business required aggressive marketing, and such expenses were necessary and of a revenue nature. The CIT(A) emphasized that the test of enduring benefit is not conclusive and that the expenses facilitated the assessee's trading operations without affecting the fixed capital.

Issue 2: Impact of Deferred Revenue Expenditure Treatment in Books
The AO's disallowance was partly based on the treatment of the expenditure as 'deferred revenue expenditure' in the assessee's books. The CIT(A) and the Tribunal held that entries in the books are not determinative of the nature of the expenses. The Tribunal referenced the Supreme Court's decision in Empire Jute Co. Ltd. vs. CIT, which stated that the test of enduring benefit is not conclusive and that the nature of the advantage in a commercial sense is what matters. The Tribunal also noted that 'deferred revenue expenditure' does not imply capital expenditure but rather revenue expenditure with benefits extending beyond the accounting year. The Tribunal concluded that the AO misconstrued the term and that the expenditure was indeed revenue in nature.

Conclusion:
The Tribunal upheld the CIT(A)'s order, confirming that the expenditure was of a revenue nature and fully allowable as claimed by the assessee. The appeal by the Revenue was dismissed.

---